Form 4: Opus Genetics CFO Nirav Jhaveri Receives Stock and Option Grants

Nirav S. Jhaveri, CFO of Opus Genetics, received grants of restricted stock units and employee stock options on March 13, 2025.

Summary

• Nirav S. Jhaveri, the Chief Financial Officer of Opus Genetics, Inc., reported changes in beneficial ownership to the SEC on March 17, 2025.
• On March 13, 2025, Jhaveri was granted 52,500 shares of common stock in the form of restricted stock units.
• These restricted stock units vest in four equal installments annually, starting on March 13, 2026, contingent upon continued service.
• Jhaveri also received an option to purchase 52,500 shares of common stock at an exercise price of $0.93 per share.
• The options vest 25% on March 13, 2026, and the remaining shares vest quarterly over the subsequent 12 quarters, also subject to continued service.
• Following these transactions, Jhaveri directly owns 194,293 shares of Opus Genetics common stock and options to purchase 52,500 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, incentivizing the CFO's continued service and aligning his interests with shareholders.

Positives

• The grant of restricted stock units and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules suggest an expectation of continued service from the CFO.

Industry Context

Stock grants and options are common compensation tools used in the biotechnology industry to attract and retain key executives, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option and RSU grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules of 4 years are typical to ensure long-term commitment.
• Comparable companies like Spark Therapeutics (acquired by Roche) and bluebird bio also utilize similar equity-based compensation strategies.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term performance.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates